Integra LifeSciences Holdings (Nasdaq: IART) reported earnings on Aug. 1. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.

Margins shrank across the board.

Revenue details
 Integra LifeSciences Holdings chalked up revenue of $205.5 million. The 15 analysts polled by S&P Capital IQ wanted to see sales of $207.5 million on the same basis. GAAP reported sales were 2.2% lower than the prior-year quarter's $210.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.60. The 15 earnings estimates compiled by S&P Capital IQ forecast $0.53 per share. Non-GAAP EPS of $0.60 for Q2 were 19% lower than the prior-year quarter's $0.74 per share. GAAP EPS of $0.12 for Q2 were 60% lower than the prior-year quarter's $0.30 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 59.6%, 490 basis points worse than the prior-year quarter. Operating margin was 3.9%, 910 basis points worse than the prior-year quarter. Net margin was 1.7%, 240 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $214.6 million. On the bottom line, the average EPS estimate is $0.71.

Next year's average estimate for revenue is $843.6 million. The average EPS estimate is $2.49.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 151 members out of 163 rating the stock outperform, and 12 members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is hold, with an average price target of $40.50.

Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.